Skip to main content
SpringerLink
Log in

Ceruloplasmin: Its Role in the Physiological and Pathological Processes

  • REVIEWS
  • Published:
Neurophysiology Aims and scope

Literature data on the role of the copper-containing metalloprotein ceruloplasmin (CP) in physiological and pathological processes, namely in health and in Wilson’s disease and other specific copper- and iron-related metabolic diseases, are reviewed. The known and supposed roles of CP in neurodegenerative, demyelinating, and cardiovascular diseases, cerebral ischemia, stroke, and traumatic CNS injuries are also analyzed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. I. N. Shanin, Antioxidant Therapy in Clinical Practice [in Russian], ÉLBI, St. Petersburg (2003).

  2. S. Silbernagl and F. Lang, Color Atlas of Pathophysiology, Thieme, Stuttgart, New York (2016).

    Google Scholar 

  3. D. V. Grigorieva, I. V. Gorudko, V. A. Kostevich, et al., “Myeloperoxidase activity in blood plasma as a criterion of therapy for patients with cardiovascular disease,” Biomed. Khim., 62, No. 3, 318–324 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. A. V. Sokolov, E. T. Zakahrova, V. A. Kostevich, et al., “Lactoferrin, myeloperoxidase, and ceruloplasmin: complementary gearwheels cranking physiological and pathological processes,” Biometals, 27, No. 5, 815–828 (2014).

    Article  CAS  PubMed  Google Scholar 

  5. D. D. Hou, R. Z. Zhu, Z. Sun, et al., “Serum proteomics analysis in rats with immunosuppression induced by chronic stress,” Scand. J. Immunol., 84, No. 3, 165–173 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. V. A. Kostevich, A. V. Sokolov, S. O. Kozlov, et al., “Functional link between ferroxidase activity of ceruloplasmin and protective effect of apo-lactoferrin: studying rats kept on a silver chloride diet,” Biometals, 29, No. 4, 691–704 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. A. Ashok, S. Karmakar, R. Chandel, et al., “Prion protein modulates iron transport in the anterior segment: Implications for ocular iron homeostasis and prion transmission,” Exp. Eye Res., 175, 1–13 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. O. Bandmann, K. H. Weiss, and S. G. Kaler, “Wilson’s disease and other neurological copper disorders,” Lancet Neurol., 14, No. 1, 103–113 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. E. B. Tapper, N. Sengupta, M. Lai, and G. Horowitz, “A decision support tool to reduce overtesting for ceruloplasmin and improve adherence with clinical guidelines,” JAMA Intern. Med., 175, No. 9, 1561–1562 (2015).

    Article  PubMed  Google Scholar 

  10. D. Plantone, G. Primiano, R. Renna, et al., “Copper deficiency myelopathy: A report of two cases,” J. Spin. Cord Med., 38, No. 4, 559–562 (2015).

    Article  Google Scholar 

  11. G. L. Calder, M. H. Lee, N. Sachithanandan, et al., “Aceruloplasminaemia: a disorder of diabetes and neurodegeneration: Brief Communications,” Intern. Med. J., 47, No. 1, 115–118 (2017).

    Article  CAS  PubMed  Google Scholar 

  12. M. Hayashida, S. Hashioka, H. Miki, et al., “Aceruloplasminemia with psychomotor excitement and neurological sign was improved by minocycline (case report),” Medicine (Baltimore), 95, No. 19, e3594 (2016).

    Article  Google Scholar 

  13. B. Wang and X.-P. Wang, “Does ceruloplasmin defend against neurodegenerative diseases?” Curr. Neuropharmacol., 17, No. 6, 539 –549 (2019).

    Article  CAS  PubMed  Google Scholar 

  14. S. Montes, S. Rivera-Mancia, A. Diaz-Ruiz, et al., “Copper and copper proteins in Parkinson’s disease,” Oxid. Med. Cell. Longev., 2014, No. 2, 1–15 (2014).

    Article  CAS  Google Scholar 

  15. L.-H. You, F. Li, L. Wang, et al., “Brain iron accumulation exacerbates the pathogenesis of MPTPinduced Parkinson’s disease,” Neuroscience, 284, 234–246 (2015).

    Article  CAS  PubMed  Google Scholar 

  16. S. Ayton, P. Lei, C. Mclean, et al., “Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson’s substantia nigra,” Sign. Transduct. Target. Ther., 1, 1–6 (2016).

    Google Scholar 

  17. C. W. Levenson and N. M. Tassabehji, “Iron and ageing: an introduction to iron regulatory mechanisms,” Ageing Res. Rev., 3, No. 3, 251–263 (2004).

    Article  CAS  PubMed  Google Scholar 

  18. G. Grolez, C. Moreau, B. Sablonnière, et al., “Cerulo-plasmin activity and iron chelation treatment of patients with Parkinson’s disease,” BMC Neurol., 15, No. 1, 74 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. A. Avan and T. U. Hoogenraad, “Zinc and copper in Alzheimer’s disease,” J. Alzheimers Dis., 46, No. 1, 89–92 (2015).

    Article  CAS  PubMed  Google Scholar 

  20. M. Schrag, C. Mueller, M. Zabel, et al., “Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: A meta-analysis,” Neurobiol. Dis., 59, 100–110 (2013).

    Article  CAS  PubMed  Google Scholar 

  21. L. Q. Lam, B. X. Wong, T. Frugier, et al., “Oxidation of iron under physiologically relevant conditions in biological fluids from healthy and Alzheimer’s disease subjects,” ACS Chem. Neurosci., 8, No. 4, 731–736 (2017).

    Article  CAS  PubMed  Google Scholar 

  22. R. Squitti, M. Siotto, and R. Polimanti, “Low-copper diet as a preventive strategy for Alzheimer’s disease,” Neurobiol. Aging, 35, Suppl. 2, S40–50 (2014).

    Article  CAS  PubMed  Google Scholar 

  23. A. Conti, S. Iannaccone, B. Sferrazza, et al., “Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients,” Proteomics Clin. Appl., 2, No. 12, 1628–1637 (2008).

    Article  CAS  PubMed  Google Scholar 

  24. S. Eryd Adamsson, J. G. Smith, O. Melander, et al., “Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study,” Eur. J. Epidemiol., 26, No. 6, 449–455 (2011).

    Article  CAS  Google Scholar 

  25. G. Engström, B. Hedblad, P. Tydén, and F. Lindgärde, “Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a populationbased cohort study,” Atherosclerosis, 202, No. 2, 617–622 (2009).

    Article  CAS  PubMed  Google Scholar 

  26. M. Hammadah, Y. Fan, Y. Wu, et al., “Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure,” J. Card. Fail., 20, No. 12, 946–952 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. D. J. Kennedy, Y. Fan, Y. Wu, et al., “Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD,” Clin. J. Am. Soc. Nephrol., 9, No. 3, 462–467 (2014).

    Article  PubMed  Google Scholar 

  28. G. Engström, B. Hedblad, L. Stavenow, et al., “Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a populationbased cohort study,” Arterioscler. Thromb Vasc. Biol., 24, No. 8, 1498–1502 (2004).

    Article  CAS  PubMed  Google Scholar 

  29. G. Engström, L. Stavenow, B. Hedblad, et al., “Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study,” Diabetes, 52, No. 2, 442–447 (2003).

    Article  PubMed  Google Scholar 

  30. P. Lind, G. Engström, L. Stavenow, et al., “Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins,” Arterioscler. Thromb Vasc. Biol., 24, No. 3, 577–582 (2004).

    Article  CAS  PubMed  Google Scholar 

  31. W. H. W. Tang, Y. Wu, J. Hartiala, et al., “Clinical and genetic association of serum ceruloplasmin with cardiovascular risk,” Arterioscler. Thromb Vasc. Biol., 32, No. 2, 516–522 (2012).

    Article  CAS  PubMed  Google Scholar 

  32. C. Altamura, R. Squitti, P. Pasqualetti, et al., “Ceruloplasmin/transferrin system is related to clinical status in acute stroke,” Stroke, 40, No. 4, 1282–1288 (2009).

    Article  CAS  PubMed  Google Scholar 

  33. I. M. Cojocaru, M. Cojocaru, V. Sapira, and A. Ionescu, “Evaluation of oxidative stress in patients with acute ischemic stroke,” Rom. J. Intern. Med., 51, No. 2, 97–106 (2013).

    CAS  PubMed  Google Scholar 

  34. B. D’Souza, V. D’Souza, S. Sowmya, et al., “A comparative study on oxidative stress and antioxidant status in ischemic stroke patients with and without diabetes,” Indian. J. Clin. Biochem., 23, No. 3, 218–222 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  35. Y. Tamam, K. Iltumur, and I. Apak, “Assessment of acute phase proteins in acute ischemic stroke,” Tohoku J. Exp. Med., 206, No. 2, 91–98 (2005).

    Article  CAS  PubMed  Google Scholar 

  36. I.M. Cojocaru, M. Cojocaru, C. Muşuroi, et al., “Study of some markers of inflammation in atherothrombotic pathogenesis of acute ischemic stroke,” Rom. J. Intern. Med., 40, Nos.1–4, 103–116 (2002).

    PubMed  Google Scholar 

  37. E. Oprea, M. Berteanu, D. Cintezã, and B.N. Manolescu, “The effect of the ALAnerv nutritional supplement on some oxidative stress markers in postacute stroke patients undergoing rehabilitation,” Appl. Physiol. Nutr. Metab., 38, No. 6, 613–620 (2013).

    Article  CAS  PubMed  Google Scholar 

  38. M. Lai, D. Wang, Z. Lin, and Y. Zhang, “Small molecule copper and its relative metabolites in serum of cerebral ischemic stroke patients,” J. Stroke Cerebrovasc. Dis., 25, No. 1, 214–219 (2016).

    Article  PubMed  Google Scholar 

  39. G. Assenza, F. Zappasodi, R. Squitti, et al., “Neuronal functionality assessed by magnetoencephalography is related to oxidative stress system in acute ischemic stroke,” NeuroImage, 44, No. 4, 1267–1273 (2009).

    Article  PubMed  Google Scholar 

  40. Q. Tuo, P. Lei, K. A. Jackman, et al., “Tau-mediated iron export prevents ferroptotic damage after ischemic stroke,” Mol. Psychiatry, 22, No. 11, 1520–1530 (2017).

    Article  CAS  PubMed  Google Scholar 

  41. H. Obara, Y. Tomite, and M. Doi, “Serum trace elements in tube-fed neurological dysphagia patients correlate with nutritional indices but do not correlate with trace element intakes: case of patients receiving enough trace elements intake,” Clin. Nutr., 27, No. 4, 587–593 (2008).

    Article  CAS  PubMed  Google Scholar 

  42. M. Siotto, I. Aprile, I. Simonelli, et al., “An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain,” J. Neural. Transm. (Vienna), 124, No. 12, 1557–1566 (2017).

    Article  CAS  Google Scholar 

  43. A. I. Konoplya, V. B. Laskov, and A. A. Shul’ginova, “Immune and oxygen disturbances in patients with chronic cerebral ischemia and their correction,” Korsakov Zh. Nevrol. Psikhiatr., 115, No. 11, 28–32 (2015).

    Article  CAS  Google Scholar 

  44. W. Deng, J. Cao, L. Chen, et al., “Plasma glycoproteomic study of therapeutic hypothermia reveals novel markers predicting neurologic outcome post-cardiac arrest,” Transl. Stroke Res., 9, No. 1, 64–73 (2018).

    Article  CAS  PubMed  Google Scholar 

  45. G. Engström, P. Lind, B. Hedblad, et al., “Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke,” Stroke, 33, No. 12, 2744–2749 (2002).

    Article  CAS  PubMed  Google Scholar 

  46. S. Ayton, M. Zhang, B.R. Roberts, et al., “Ceruloplasmin and β-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron,” Free Radic. Biol. Med., 69, 331–337 (2014).

    Article  CAS  PubMed  Google Scholar 

  47. K. I. Rathore, B. J. Kerr, A. Redensek, et al., “Ceruloplasmin protects injured spinal cord from ironmediated oxidative damage,” J. Neurosci., 28, No. 48, 12736–12747 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. M. Adamczyk-Sowa, P. Sowa, S. Mucha, et al., “Changes in serum ceruloplasmin levels based on immunomodulatory treatments and melatonin supplementation in multiple sclerosis patients,” Med. Sci. Monit., 22, 2484–2491 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  49. V. M. Provotorov, A. V. Budnevsky, and Y. I. Filatova, “Clinical manifestations of asthma during combination therapy using ceruloplasmin,” Ter. Arkh., 88, No. 3, 36–39 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

    V. V. Orzheshkovskyi & M. A. Trishchynska

Authors
  1. V. V. Orzheshkovskyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Trishchynska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. V. Orzheshkovskyi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orzheshkovskyi, V.V., Trishchynska, M.A. Ceruloplasmin: Its Role in the Physiological and Pathological Processes. Neurophysiology 51, 141–149 (2019). https://doi.org/10.1007/s11062-019-09805-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11062-019-09805-9

Keywords

Search

Navigation